Latest Headlines

Latest Headlines

Pearl lands $65M round to fuel PhIII COPD showdown with Novartis, GSK

Pearl Therapeutics has grabbed a hefty $65 million venture round, enough to bankroll the launch of a key late-stage COPD drug program that--one way or another--will prove transformational for the biotech.

Pearl's combo COPD treatment beats market rivals as it races to Ph3

Pearl Therapeutics put its combo LAMA/LABA treatment for COPD--PT003--up against two standard treatments for the lung disease and says it emerged with a commanding lead based on a key method for

Pearl reports inhaled COPD drug results

Pearl Therapeutics has reported results from four studies supporting further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized